

October 26, 2016


## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-02)	SAVOLITINIB
PRONUNCIATION	sav" oh li' ti nib
THERAPEUTIC CLAIM	Treatment of cancer

## CHEMICAL NAMES

1. 1*H*-1,2,3-Triazolo[4,5-*b*]pyrazine, 1-[(1*S*)-1-imidazo[1,2-*a*]pyridin-6-ylethyl]-6-(1-methyl-1*H*-pyrazol-4-yl)-
2. 1-[(1*S*)-1-(imidazo[1,2-*a*]pyridin-6-yl)ethyl]-6-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-1,2,3-triazolo[4,5-*b*]pyrazine

## STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>17</sub> H <sub>15</sub> N <sub>9</sub>
MOLECULAR WEIGHT	345.4
TRADEMARK	None as yet
SPONSOR	AstraZeneca
CODE DESIGNATIONS	AZD6094, HMPL-504
<u>CAS</u> REGISTRY NUMBER	1313725-88-0
UNII	2A2DA6857R
WHO NUMBER	9935

gbk